The Michael J Fox Foundation
Sumitomo Pharma’s stem cell therapy for Parkinson’s given limited approval in Japan
The company has been given manufacturing and marketing authorisation for the therapy
Annovis partners with NeuroRPM on new AI platform to track Parkinson’s symptoms
The platform will passively collect data to understand treatment responses in everyday life
Mission Therapeutics advances Parkinson’s disease candidate
The company also received a grant from the Michael J. Fox Foundation and Parkinson’s UK
Biogen expands portfolio in deal with Alcyone Therapeutics
The agreement gives Biogen full rights to a potential therapy for patients with neurological disorders
PhotoPharmics’ new advisory board to guide launch of FDA Breakthrough device for Parkinson’s
The US-based company develops light-based therapies for neurodegenerative conditions
GSK and Vesalius partner on new Parkinson’s treatments in deal worth $650m
The alliance is aimed at developing treatments for Parkinson's and another neurodegeneration indication
Sanofi’s investigational frexalimab shows promise in relapsing MS study
Approximately 2.9 million people worldwide are affected by the neurological disease
Researchers develop AI blood test to predict Parkinson’s seven years before symptom onset
The neurodegenerative condition currently affects nearly ten million people worldwide
Roche and Ascidian enter neurological disease partnership worth over $1.8bn
More than three billion people worldwide were living with a neurological condition in 2021
Tiziana shares promising results for intranasal foralumab in secondary progressive MS
The neurological disease is estimated to affect 2.8 million people globally
Tiziana shares promising results for intranasal foralumab in multiple sclerosis
The neurological disease affects approximately 2.8 million people worldwide
Cerevel Therapeutics shares positive phase 3 results for tavapadon in Parkinson’s disease
The progressive neurodegenerative disease affects seven million people worldwide